Focused On-demand Library for Eukaryotic translation initiation factor 4E type 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O60573

UPID:

IF4E2_HUMAN

Alternative names:

Eukaryotic translation initiation factor 4E homologous protein; Eukaryotic translation initiation factor 4E-like 3; eIF4E-like protein 4E-LP; mRNA cap-binding protein 4EHP; mRNA cap-binding protein type 3

Alternative UPACC:

O60573; B8ZZJ9; O75349

Background:

Eukaryotic translation initiation factor 4E type 2 (EIF4E2) is a pivotal protein in cellular mechanisms, primarily recognized for its role in binding the 7-methylguanosine-containing mRNA cap, a crucial step in the initiation of translation. Unlike EIF4E, EIF4E2 does not bind to eIF4G, indicating its unique function in competing with EIF4E to inhibit the assembly of the eIF4F complex at the mRNA cap. Additionally, EIF4E2 is a key player in miRNA-mediated translational repression and is involved in the cellular response to viral infections, including SARS-CoV-2, by modulating the translation initiation of genes critical to the antiviral immune response.

Therapeutic significance:

Understanding the role of Eukaryotic translation initiation factor 4E type 2 could open doors to potential therapeutic strategies, especially in the context of viral infections and the regulation of immune response genes.